Background Over the last 15 years, a paradigm shift in oncology has led to the approval of
dozens of targeted oral anti-cancer medications (OAMs), which have become the standard …

Background The prevalence of patients with gastrointestinal stromal tumourgst (GIST) who
fail currently available treatments imatinib and sunitinib (third-line treatment-eligible GIST) is …

Abstract Background Cost-utility analyses (CUAs) increasingly use models to predict long-
term outcomes and translate trial data to real-world settings. Model structure uncertainty …

Concomitant radiochemotherapy followed by six cycles of temozolomide (= short term) is
considered as standard therapy for adults with newly diagnosed glioblastoma. In contrast …

Abstract Background and Objective Precision (stratified or personalised) medicine is
underpinned by the premise that it is feasible to identify known heterogeneity using a …

Over the past 20 years, with the incorporation of genetic sequencing and improved
understanding regarding the mechanisms of cancer growth/metastasis, novel targets and …

BACKGROUND Imatinib dose escalation is advocated for gastrointestinal stromal tumour
(GIST) treatment, but its effectiveness compared with sunitinib and best supportive care …

Background: Recent clinical trial data have demonstrated that 3 years vs 1 year of adjuvant
imatinib therapy for patients with surgically resected Kit+ Gastrointestinal Stromal Tumors …

Background: The introduction of tyrosine kinase inhibitor (TKI) therapy has dramatically
improved the clinical effectiveness of patients with locally advanced and/or metastatic …

Background The INVICTUS trial assessed the efficacy and safety of ripretinib compared with
placebo in the management of advanced gastrointestinal stromal tumors. Method We used a …